NervGen Pharma (9UA) Price & Analysis

3 Followers

9UA Stock Chart & Stats

€1.79

-€0.05(-3.50%)

At close: Jul 31 4:00 PM EDT

€1.79

-€0.05(-3.50%)

Day’s Range― - ―

52-Week Range€1.27 - €5.00

Previous CloseN/A

Volume0.00

Average Volume (3M)926.00

Market Cap

€212.49M

Enterprise Value€129.26

Total Cash (Recent Filing)€86.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Nov 12, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.85

Shares Outstanding107,522,640

10 Day Avg. Volume493

30 Day Avg. Volume926

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)159.85

Price to Sales (P/S)0.00

P/FCF Ratio-28.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€10.88

Price Target Upside507.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.34

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageNear-zero debt limits mandatory interest and principal payments, preserving flexibility while NervGen funds clinical development. This gives the company a stronger balance-sheet position than a similarly unprofitable biotech carrying substantial leverage, although it does not remove its need for capital.

Improved Capitalization And LiquidityThe sharp increase in cash and assets strengthens NervGen’s ability to continue trials and corporate operations over the coming quarters. A larger liquidity cushion can reduce immediate financing pressure and provide more time to advance NVG-291 development before additional funding is required.

Focused Clinical PipelineA lead program aimed at nervous-system repair gives NervGen a focused development strategy and potential applicability across multiple neurological indications. If clinical development supports the candidate’s potential, this breadth could expand partnering or commercialization opportunities beyond a single use case.

Bears Say

No Commercial RevenueNervGen currently lacks recurring product revenue to fund research, trials, or corporate expenses. Until a candidate is approved and commercialized, the business remains dependent on financing, licensing, or collaboration proceeds, making progress vulnerable to development outcomes and capital availability.

Widening Losses And Cash BurnEscalating losses and increasingly negative operating cash flow show that spending is rising faster than any internally generated funding. Persistent burn will require continued access to external capital and may constrain the pace of development or force less favorable financing decisions.

Shareholder Dilution ExposureThe ATM facility provides funding flexibility but creates a direct route to dilution as shares are issued. The enlarged warrant liability adds financial complexity and potential volatility, while repeated equity financing can reduce existing holders’ ownership as the clinical program consumes cash.

NervGen Pharma News

NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year

“With FDA alignment and funding to support RESTORE now in place, we have expanded our organization with experienced...

1M ago

NGEN

NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position

NervGen Pharma ( ($NGEN) ) has issued an update. NervGen Pharma Corp., a Vancouver-based biotechnology company specializing in...

1M ago

NGEN

NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18...

2M ago

NGEN

NervGen Pharma initiated with an Outperform at Leerink

Leerink analyst Marc Goodman initiated coverage of NervGen Pharma (NGEN) with an Outperform rating and $10 price target...

2M ago

NGEN

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

NervGen Pharma ( ($NGEN) ) has issued an update. On July 2, 2026, NervGen Pharma filed a Form...

3M ago

NGEN

NervGen Pharma initiated with a Buy at TD Cowen

TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company...

3M ago

NGEN

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma priced an underwritten...

4M ago

NGEN

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

Nervgen Pharma Corp ($NGEN) announced an update on their ongoing clinical study. The CONNECT study, officially titled “A...

4M ago

NGEN

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

NervGen Pharma ( ($NGEN) ) has provided an update. On May 26, 2026, NervGen Pharma reported independently conducted,...

4M ago

NGEN

NervGen Pharma files $250M mixed securities shelf

09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

NGEN

NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291

NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the...

4M ago

NGEN

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development

NervGen Pharma ( ($NGEN) ) has shared an announcement. On May 21, 2026, NervGen Pharma announced it had...

4M ago

NGEN

NervGen Pharma 24M share Spot Secondary priced at $2.50

Leerink and TD Cowen acted as joint book running managers for the offering. Published first on TheFly –...

4M ago

NGEN

NervGen Pharma secondary being re-offered at $2.50 per share

Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering. Published first on TheFly...

4M ago

NGEN

9UA FAQ

What was NervGen Pharma’s price range in the past 12 months?

NervGen Pharma lowest stock price was €1.27 and its highest was €5.00 in the past 12 months.

What is NervGen Pharma’s market cap?

NervGen Pharma’s market cap is €212.49M.

When is NervGen Pharma’s upcoming earnings report date?

NervGen Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 54 days.

How were NervGen Pharma’s earnings last quarter?

NervGen Pharma released its earnings results on Aug 13, 2026. The company reported -€0.227 earnings per share for the quarter, missing the consensus estimate of -€0.052 by -€0.175.

Is NervGen Pharma overvalued?

According to Wall Street analysts NervGen Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NervGen Pharma pay dividends?

NervGen Pharma does not currently pay dividends.

What is NervGen Pharma’s EPS estimate?

NervGen Pharma’s EPS estimate is -0.08.

How many shares outstanding does NervGen Pharma have?

NervGen Pharma has 107,522,640 shares outstanding.

What happened to NervGen Pharma’s price movement after its last earnings report?

NervGen Pharma reported an EPS of -€0.227 in its last earnings report, missing expectations of -€0.052. Following the earnings report the stock price went up 2.837%.

Which hedge fund is a major shareholder of NervGen Pharma?

Currently, no hedge funds are holding shares in DE:9UA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

NervGen Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

412.55%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

NervGen Pharma

NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.

NervGen Pharma (9UA) Earnings & Revenues

Historic Earnings Reports

9UA Stock 12 Month Forecast

Average Price Target

€10.88

▲(507.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.05905835,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.882548625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.7060389,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,2.5460814115384616,3.422162823076923,4.298244234615385,5.1743256461538465,6.050407057692308,6.92648846923077,7.802569880769232,8.678651292307693,9.554732703846154,10.430814115384615,11.306895526923078,12.18297693846154,{"y":13.05905835,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,2.3786575865384614,3.087315173076923,3.7959727596153847,4.504630346153846,5.213287932692308,5.9219455192307695,6.6306031057692305,7.339260692307692,8.047918278846154,8.756575865384615,9.465233451923076,10.173891038461539,{"y":10.882548625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.67,2.2112337615384616,2.752467523076923,3.293701284615384,3.834935046153846,4.3761688076923075,4.917402569230768,5.45863633076923,5.999870092307692,6.5411038538461534,7.082337615384615,7.623571376923076,8.164805138461539,{"y":8.7060389,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >